|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01011 NT PHARMA
Nominal 
0.345 +0.010 (+2.985%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 7,366 | -96.443% | 207,092 | 226,699 | 221,731 | 365,969 |
| Cost of Sales | -- | -- | (81,806) | (81,240) | (86,827) | (105,086) |
| Gross Profit | -- | -- | 125,286 | 145,459 | 134,904 | 260,883 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | (78) | -- | 10,980 | (10,980) | |
| Change in FV & Impairment on Others | -- | -- | -- | (14,011) | (68,706) | (340,147) | |
| Profit / (Loss) on Disposal | 12,272 | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | (11,318) | (5,807) | -- | -- | |
| Share of Results of Asso. & JCEs | 37,039 | 311.407% | 9,003 | 34,490 | 8 | (27) | |
| Profit / (Loss) before Taxation | (33,369) | -38.542% | (54,296) | (148,752) | (200,289) | (583,472) | |
| Taxation | (122) | -98.992% | (12,109) | (2,582) | 9,020 | (9,730) | |
| Profit / (Loss) from Discontinued Operations | (110,099) | -- | -- | -- | (168,644) | -- | |
| Non-controlling Interests | 0 | -- | 0 | 1,796 | 2,314 | 5,612 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (143,590) | 116.234% | (66,405) | (149,538) | (357,599) | (587,590) | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 28,809 | -59.826% | 71,710 | 88,488 | 83,702 | 102,491 |
| Depreciation & Amortisation | 1,213 | -94.243% | 21,070 | 42,249 | 24,397 | 31,131 |
| Directors' Emoluments | 2,231 | -38.182% | 3,609 | 3,774 | 4,417 | 20,178 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Disclaimer | -- | Disclaimer | Disclaimer | Unqualified (Modified Report) | Unqualified (Modified Report) |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | -72.600 | 108.023% | -34.900 | -79.100 | -189.500 | -333.100 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | 0.255 | -- | 0.191 | (0.072) | 0.014 | 0.027 |
| NBV per share ($) | (1.286) | -- | (1.269) | (1.109792) | 0.08547 | 0.552641 |
| Remarks: | Real time quote last updated: 01/11/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB 661,000 |
| %Change | -- |
| EPS / (LPS) | RMB 0.000 |
| NBV Per Share (¥) | RMB -0.131 |